Aaron Franke is an Oncology physician affiliated with Northern Plains Agricultural Research Laboratory. OpenAlex indexes 43 publications with 652 citations (h-index 10).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
216 14th Ave SW
Sidney, MT 592703519
Telephone
406-488-2504Provider last certified this registry record 1 Jul 2023.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Tempus AI, IncProgram year20252 payments
- Adaptive Biotechnologies CorporationProgram year20252 payments
- Novocure Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
30.4%Aromatase Inhibitor15.2%Letrozole100%Part D≥13 patientsAntimetabolite5.8%Hydroxyurea100%Part D<11 patients+ 2 more classes in this area
Metabolism & gastrointestinal
26.5%Serotonin-3 Receptor Antagonist14.8%Ondansetron Hcl58%Ondansetron Odt42%Part D<11 patientsCorticosteroid11.7%Prednisone100%Part D<11 patientsNervous system
20.2%Phenothiazine13.2%Prochlorperazine Maleate100%Part D≥26 patientsAtypical Antipsychotic7%Olanzapine100%Part D≥15 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Re-ORIENT-ing antitumor immunity in EGFR-mutant non-small cell lung cancer: are antiangiogenics the key?
Chinese Clinical Oncology
2023 - Results of a phase II trial of the PARP inhibitor, niraparib, in BAP1 and other DNA damage response pathway deficient neoplasms.
Journal of Clinical Oncology
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”